345 related articles for article (PubMed ID: 12013545)
1. The use of toxicokinetic and toxicodynamic data in risk assessment: an international perspective.
Gundert-Remy U; Sonich-Mullin C;
Sci Total Environ; 2002 Apr; 288(1-2):3-11. PubMed ID: 12013545
[TBL] [Abstract][Full Text] [Related]
2. Practical application of kinetic data in risk assessment--an IPCS initiative.
Meek B; Renwick A; Sonich-Mullin C;
Toxicol Lett; 2003 Feb; 138(1-2):151-60. PubMed ID: 12559699
[TBL] [Abstract][Full Text] [Related]
3. Toxicokinetic and toxicodynamic considerations when deriving health-based exposure limits for pharmaceuticals.
Reichard JF; Maier MA; Naumann BD; Pecquet AM; Pfister T; Sandhu R; Sargent EV; Streeter AJ; Weideman PA
Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 1():S67-78. PubMed ID: 27224509
[TBL] [Abstract][Full Text] [Related]
4. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
EFSA GMO Panel Working Group on Animal Feeding Trials
Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
[TBL] [Abstract][Full Text] [Related]
5. Deriving a data-based interspecies assessment factor using the NOAEL and the benchmark dose approach.
Bokkers BG; Slob W
Crit Rev Toxicol; 2007 Jun; 37(5):355-73. PubMed ID: 17612951
[TBL] [Abstract][Full Text] [Related]
6. Uncertainty factors for chemical risk assessment: interspecies differences in glucuronidation.
Walton K; Dorne JL; Renwick AG
Food Chem Toxicol; 2001 Dec; 39(12):1175-90. PubMed ID: 11696391
[TBL] [Abstract][Full Text] [Related]
7. Framework for human health risk assessment of non-cancer effects resulting from short-duration and intermittent exposures to chemicals.
Haber LT; Sandhu R; Li-Muller A; Mohapatra A; Petrovic S; Meek ME
J Appl Toxicol; 2016 Sep; 36(9):1077-89. PubMed ID: 27297613
[TBL] [Abstract][Full Text] [Related]
8. Human risk assessment of dermal and inhalation exposures to chemicals assessed by route-to-route extrapolation: the necessity of kinetic data.
Geraets L; Bessems JG; Zeilmaker MJ; Bos PM
Regul Toxicol Pharmacol; 2014 Oct; 70(1):54-64. PubMed ID: 24912090
[TBL] [Abstract][Full Text] [Related]
9. Incorporating population variability and susceptible subpopulations into dosimetry for high-throughput toxicity testing.
Wetmore BA; Allen B; Clewell HJ; Parker T; Wambaugh JF; Almond LM; Sochaski MA; Thomas RS
Toxicol Sci; 2014 Nov; 142(1):210-24. PubMed ID: 25145659
[TBL] [Abstract][Full Text] [Related]
10. Implementing Toxicity Testing in the 21st Century (TT21C): Making safety decisions using toxicity pathways, and progress in a prototype risk assessment.
Adeleye Y; Andersen M; Clewell R; Davies M; Dent M; Edwards S; Fowler P; Malcomber S; Nicol B; Scott A; Scott S; Sun B; Westmoreland C; White A; Zhang Q; Carmichael PL
Toxicology; 2015 Jun; 332():102-11. PubMed ID: 24582757
[TBL] [Abstract][Full Text] [Related]
11. Uncertainty and variability in human exposure limits - a chemical-specific approach for ciprofloxacin and methotrexate.
Oldenkamp R; Huijbregts MA; Ragas AM
Crit Rev Toxicol; 2016; 46(3):261-78. PubMed ID: 26648512
[TBL] [Abstract][Full Text] [Related]
12. Precision of estimates of an ADI (or TDI or PTWI).
Speijers GJ
Regul Toxicol Pharmacol; 1999 Oct; 30(2 Pt 2):S87-93. PubMed ID: 10597619
[TBL] [Abstract][Full Text] [Related]
13. Biokinetic and toxicodynamic modelling and its role in toxicological research and risk assessment.
Blaauboer BJ
Altern Lab Anim; 2003; 31(3):277-81. PubMed ID: 15612871
[TBL] [Abstract][Full Text] [Related]
14. A procedure for developing risk-based reference doses.
Gaylor DW; Kodell RL
Regul Toxicol Pharmacol; 2002 Apr; 35(2 Pt 1):137-41. PubMed ID: 12051999
[TBL] [Abstract][Full Text] [Related]
15. Internal threshold of toxicological concern values: enabling route-to-route extrapolation.
Partosch F; Mielke H; Stahlmann R; Kleuser B; Barlow S; Gundert-Remy U
Arch Toxicol; 2015 Jun; 89(6):941-8. PubMed ID: 24915937
[TBL] [Abstract][Full Text] [Related]
16. Probabilistic framework for the estimation of the adult and child toxicokinetic intraspecies uncertainty factors.
Pelekis M; Nicolich MJ; Gauthier JS
Risk Anal; 2003 Dec; 23(6):1239-55. PubMed ID: 14641898
[TBL] [Abstract][Full Text] [Related]
17. Background to the ADI/TDI/PTWI.
Herrman JL; Younes M
Regul Toxicol Pharmacol; 1999 Oct; 30(2 Pt 2):S109-13. PubMed ID: 10597623
[TBL] [Abstract][Full Text] [Related]
18. Evolution of chemical-specific adjustment factors (CSAF) based on recent international experience; increasing utility and facilitating regulatory acceptance.
Bhat VS; Meek MEB; Valcke M; English C; Boobis A; Brown R
Crit Rev Toxicol; 2017 Oct; 47(9):729-749. PubMed ID: 28681680
[TBL] [Abstract][Full Text] [Related]
19. Metabolism, variability and risk assessment.
Dorne JL
Toxicology; 2010 Feb; 268(3):156-64. PubMed ID: 19932147
[TBL] [Abstract][Full Text] [Related]
20. Assessment of health risks resulting from early-life exposures: Are current chemical toxicity testing protocols and risk assessment methods adequate?
Felter SP; Daston GP; Euling SY; Piersma AH; Tassinari MS
Crit Rev Toxicol; 2015 Mar; 45(3):219-44. PubMed ID: 25687245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
